II. Indications

III. Mechanism

  1. See ACE Inhibitor
  2. Non-sulfhydryl Angiotensin Converting Enzyme (ACE) inhibitor
  3. Moexipril is a prodrug, converted to its active form Moexiprilat via hydrolysis

IV. Dosing

  1. Adequate 24 hour Blood Pressure control may require twice daily dosing
  2. Take one hour before meals
  3. Hypertension
    1. Start 7.5 mg orally daily
      1. Start 3.75 mg orally daily in renal dysfunction
    2. Target 7.5 to 30 mg orally daily or divided twice daily
    3. Maximum 30 mg/day (15 mg/day in renal dysfunction)

V. Supplied

  1. Available as generic scored tablets (7.5, 15 mg)

VI. Metabolism

  1. Primarily hepatic metabolism

VII. Adverse Effects

VIII. Safety

  1. See ACE Inhibitor
  2. Pregnancy Category X
  3. Avoid in Lactation

X. References

  1. (2016) Presc Lett, Resource #321151, ACE Inhibitor Antihypertensive Dose Comparison
  2. (2020) Med Lett Drugs Ther 62(1598): 73-80
  3. Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 68-9
  4. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

moexipril (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
MOEXIPRIL HCL 15 MG TABLET Generic $0.75 each
MOEXIPRIL HCL 7.5 MG TABLET Generic $0.97 each

Ontology: moexipril (C0066685)

Definition (NCI) A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, moexipril is hydrolyzed into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C058302
SnomedCT 108566003, 373442003
English 2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, moexipril, MOEXIPRIL, moexipril [Chemical/Ingredient], Moexipril, Moexipril (product), Moexipril (substance)
Spanish moexipril (producto), moexipril (sustancia), moexiprilo, moexipril

Ontology: Univasc (C0724125)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C058302
English univasc, Perdix, Moex, Schwarz brand of moexipril hydrochloride, Univasc